GH Research (NASDAQ:GHRS) Trading Up 4.1% – Still a Buy?

GH Research PLC (NASDAQ:GHRS)’s stock price was up 4.1% during trading on Tuesday . The company traded as high as $9.66 and last traded at $9.41. Approximately 15,035 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 79,072 shares. The stock had previously closed at $9.04.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and set a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th.

GH Research Stock Performance

The stock’s 50-day moving average price is $7.74 and its 200-day moving average price is $10.39. The company has a market capitalization of $466.71 million, a price-to-earnings ratio of -13.82 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Analysts anticipate that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research comprises approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).